Advertisement
Research Article

Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer

  • Anne P. G Crijns equal contributor,

    equal contributor Contributed equally to this work with: Anne P. G Crijns, Rudolf S. N Fehrmann

    Affiliation: Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Rudolf S. N Fehrmann equal contributor,

    equal contributor Contributed equally to this work with: Anne P. G Crijns, Rudolf S. N Fehrmann

    Affiliations: Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands, Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands, Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Steven de Jong,

    Affiliation: Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Frans Gerbens,

    Affiliation: Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Gert Jan Meersma,

    Affiliation: Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Harry G Klip,

    Affiliation: Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Harry Hollema,

    Affiliation: Department of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Robert M. W Hofstra,

    Affiliation: Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Gerard J. te Meerman,

    Affiliation: Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Elisabeth G. E de Vries,

    Affiliation: Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Ate G. J van der Zee mail

    To whom correspondence should be addressed. E-mail: A.G.J.van.der.Zee@og.umcg.nl

    Affiliation: Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    X
  • Published: February 03, 2009
  • DOI: 10.1371/journal.pmed.1000024

Reader Comments (1)

Post a new comment on this article

clinical utility? optimally cytoreduced?

Posted by plosmedicine on 31 Mar 2009 at 00:34 GMT

Author: Arvind Bakhru
Position: Resident
Institution: Univ of Maryland
E-mail: abakhru@gmail.com
Submitted Date: March 01, 2009
Published Date: March 2, 2009
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

In your aritcle, it is mentioned that in the multivariate analysis:
"Age, stage, grade, debulking status, and chemotherapy regimens showed no difference in distribution between the predicted low- and
high-risk groups."
In the multivariate analysis, only the OSP and debulking status were significant.

This seems to indicate that all these genese together creating a genetic profile is equivalent to our standard age/stage/grade for predicting final survival outcome for patients. Is there, then, clinical utility for determining the genetic profile? Clearly there are therapeutic and research opportunities presented by this paper.

Moreover, it would be nice to know if you have the data for debulking less than 1cm and less than 0.5cm. The authors used 2cm, but most U.S. centers use less than 1cm or less than 0.5cm or no visible disease as 'optimally cytoreduced' - see sloan kettering data. It may make that variable much stronger...

No competing interests declared.